Suppr超能文献

致癌轴YAP/MYC/EZH2损害PTEN的肿瘤抑制活性,增强肺肿瘤发生能力。

The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity.

作者信息

Lo Sardo Federica, Turco Chiara, Messina Beatrice, Sacconi Andrea, Auciello Francesca Romana, Pulito Claudio, Strano Sabrina, Lev Sima, Blandino Giovanni

机构信息

Translational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Clinical Trial Center, Biostatistics and Bioinformatics Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Cell Death Discov. 2024 Oct 25;10(1):452. doi: 10.1038/s41420-024-02216-8.

Abstract

The tumor suppressor PTEN (phosphatase and tensin homolog deleted in chromosome 10) is genetically deleted or downregulated in many cancer types. Loss of PTEN protein expression is frequently found in lung cancer while genetic alterations are less abundant. PTEN expression is regulated at multiple genetic and epigenetic levels and even partial reduction of its expression increases cancer occurrence. We show that YAP and TAZ cooperate with EZH2, and MYC to transcriptionally repress onco-suppressor genes, including PTEN, in non-small cell lung cancer (NSCLC) cells. YAP/TAZ-EZH2-MYC transcriptional regulators form a nuclear complex that represses PTEN transcription, while their combinatorial targeting restores PTEN expression, attenuates NSCLC cell growth, and prevents compensatory responses induced by single treatments. Datasets analysis of NSCLC patients revealed that PTEN expression is negatively correlated to YAP/TAZ, EZH2 and MYC and that low expression of PTEN is predictive of poor prognosis, especially at earlier stages of the disease. These findings highlight the repressive role of the YAP/TAZ-EZH2-MYC axis on tumor-suppressor genes and offer a potential therapeutic strategy for lung cancer patients with low PTEN levels.

摘要

肿瘤抑制因子PTEN(第10号染色体缺失的磷酸酶和张力蛋白同源物)在多种癌症类型中发生基因缺失或表达下调。PTEN蛋白表达缺失在肺癌中很常见,而基因改变则较少见。PTEN的表达在多个基因和表观遗传水平上受到调控,即使其表达出现部分降低也会增加癌症的发生。我们发现,在非小细胞肺癌(NSCLC)细胞中,YAP和TAZ与EZH2以及MYC协同作用,转录抑制包括PTEN在内的肿瘤抑制基因。YAP/TAZ-EZH2-MYC转录调节因子形成一个核复合物,抑制PTEN转录,而它们的联合靶向作用可恢复PTEN表达,减弱NSCLC细胞生长,并防止单一治疗诱导的代偿反应。对NSCLC患者的数据集分析显示,PTEN表达与YAP/TAZ、EZH2和MYC呈负相关,且PTEN低表达预示着预后不良,尤其是在疾病的早期阶段。这些发现突出了YAP/TAZ-EZH2-MYC轴对肿瘤抑制基因的抑制作用,并为PTEN水平低的肺癌患者提供了一种潜在的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00dc/11511861/3088b3546647/41420_2024_2216_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验